CervoMed Inc.
$3.97
▲
3.5%
2026-04-21 06:15:00
www.cervomed.com
NCM: CRVO
Explore CervoMed Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$36.76 M
Current Price
$3.97
52W High / Low
$13.13 / $3.51
Stock P/E
—
Book Value
$1.97
Dividend Yield
—
ROCE
-155.27%
ROE
-93.92%
Face Value
—
EPS
$-2.98
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
15
Beta
-5.04
Debt / Equity
—
Current Ratio
4.91
Quick Ratio
4.91
Forward P/E
-2.26
Price / Sales
8.85
Enterprise Value
$14.6 M
EV / EBITDA
—
EV / Revenue
3.64
Rating
Strong Buy
Target Price
$22.14
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
| 2. | Liminatus Pharma, Inc. | $0.22 | — | $9.83 M | — | 30.51% | — | $33.66 / $0.16 | $-0.06 |
| 3. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 4. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 5. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
| 6. | Context Therapeutics Inc. | $2.26 | — | $223.27 M | — | -65.65% | -46.39% | $3.62 / $0.49 | $0.66 |
| 7. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.33 M | -8.04 M | -6.62 M | -5.3 M | -7.24 M | — |
| Net Profit | -8.09 M | -7.73 M | -6.26 M | -4.89 M | -6.71 M | — |
| EPS in Rs | -0.87 | -0.83 | -0.68 | -0.53 | -0.72 | -0.55 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -28.29 M | -18.23 M | -7.81 M | -3.48 M |
| Net Profit | -26.97 M | -16.29 M | -2.17 M | -5.8 M |
| EPS in Rs | -2.91 | -1.76 | -0.23 | -0.63 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 22.88 M | 43.08 M | 9.97 M | 4.16 M |
| Total Liabilities | 4.66 M | 3.88 M | 2.6 M | 37.44 M |
| Equity | 18.22 M | 39.2 M | 7.38 M | -33.29 M |
| Current Assets | 22.88 M | 43.08 M | 9.96 M | 4.16 M |
| Current Liabilities | 4.66 M | 3.88 M | 2.6 M | 13.16 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.45 M | -16.53 M | -7.45 M | -2.57 M |
| Investing CF | 18.1 M | -28.66 M | 0 M | -12.24 M |
| Financing CF | 4.59 M | 46.4 M | 11.15 M | 0 M |
| Free CF | -23.45 M | -16.53 M | -7.45 M | -2.57 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -650.08% | 62.57% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-08-17 | 1:0.666667 |
| 2022-04-19 | 1:0.02 |